Ophthalmology in China ›› 2014, Vol. 23 ›› Issue (6): 380-384.doi: 10.13281/j.cnki.issn.1004-4469.2014.06.006

Previous Articles     Next Articles

Short-term effect of intravitreal injection Ranibizumab on intraocular pressure in wet age-related macular degeneration patients

SONG Shuang, YU Xiao-bing,  DAI Hong   

  1. Department of Ophthalmology, Beijing Hospital, Beijing 100730, China
  • Received:2014-11-01 Online:2014-11-25 Published:2014-12-01
  • Contact: DAI Hong, Email: dai-hong@x263.net E-mail:dai-hong@x263.net

Abstract: Objective To observe the short-term effect of intravitreal injection Ranibizumab(Lucentis) on intraocular pressure (IOP). Design Prospective case series. Paticipants  135 eyes from 135 patients (70.54±8.69 y) with wet age-related macular degeneration treated with Ranibizumab in Beijing Hospital. Methods  The IOP were measured by  non-contact tonometer before injection, and at 10, 30,120 minutes and 1 day after injection in a sitting position. Main Outcome Measures  The IOP pre and post-injection. Results    Mean IOP was (15.41±2.69)mmHg , (21.07±5.83) mmHg, (18.24±4.17)mmHg, (17.57±4.60 )mmHg, (15.20±3.05)mmHg, respectively, for the time points immediately before, 10,  30, 120 minutes, and 1 day after injection. Differences of IOP  between before and after injection were statistically significant at 10, 30, 120 minutes (all P<0.05) except 1 day (P=0.239); The ratio of  increasing IOP  gradually decreased after injection, and the ratio at 10 minutes was significantly higher than other times (the ratio of  IOP≥21 mmHg was 45.93%, ≥25 mmHg was 21.48%, ≥30 mmHg was 8.15%; the ratio of IOP  increasing 10 mmHg was 17.78%, increasing 15 mmHg  was 5.19%). The higher the baseline IOP was the more patients with abnormal IOP postinjection occured (P=0.000, OR=0.117, 95%CI: 0.051-0.268).  Conclusion   Intravitreal injection Ranibizumab  (Lucentis) causes a considerable short-term transient rise on IOP in most of wet age-related macular degeneration patients. The IOP increase can be statistically significant from 10 minutes to 2 hours after injection. The high baseline IOP may be a risk factor for short-term rise on IOP postinjection.

Key words: age-related macular degeneration, wet/therapy; , ranibizumab; , intraocular pressure, intravitreal injection